🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Amazing experience at #EuroPCR 2023 🇫🇷! Great sessions and good time with many colleagues and friends! Thanks to #HartCentrum #ZNA team ❤️ Pierfrancesco Agostoni Gianluca Castaldi Enrico Poletti Alice Moroni Giovanni Vescovo Andrea Bezzeccheri

Unveiling latest-gen TAVR performance in pure severe native aortic valve regurgitation. Just released in JACC Journals, the PANTHEON study focuses on cutting-edge THV platforms in this specific scenario. #JACCINT #CardioTwitter #TAVR

The Progress-AF study: 🎯 dynamic changes of LA substrate over time following PVI 👉Regression occurs with ⬇️ #AFib burden 👉Progression occurs with persistent AF 📖 shorturl.at/tDP03 European Society of Cardiology Journals Giulio Conte Dominik Linz Francesco Santoro, MD, PhD Xiaodong Zhang (Andy), MD, PhD, FHRS, FACC Marco Vitolo Ⓜ️

Bravo Lorenzo Marcon

💥Check out the results of our in-vitro validation of coronary physiology assessment with 5F guiding catheter! 🔬 🎯great level of agreement with 6F guiding catheter 🎯very high reproducibility #FullPhysiology #CoronaryPhysiology authors.elsevier.com/c/1hxgk5XJLH2q…

authors.elsevier.com/a/1i9rq6uPJvqi… Please enjoy our editorial on 2 relevant papers from the group of Emmanouil Brilakis (the #PROGRESS registry) assessing pro and contra of #ADR and #retro techniques in #CTO #PCI. Thanks to Enrico Poletti and Carlo Zivelonghi.

Thanks to all centers who participated (Angelo Quagliana, Flavio Ribichini ) And as always proud of our team (Enrico Poletti , Edgard Prihadi)!

Excited to share our PURPOSE study on the Trilogy JenaValve system for aortic regurgitation. ➡️ Higher success: lower THV embolization, second valve, and residual AR. JVT offers hope for inoperable AR patients. #JACCJournals #TAVR #JenaValve #AorticRegurgitation

Predicting hemodynamics collapse requiring bailout #MCS: the holy grail of #PCI. Interesting data presented at Cardiovascular Research Foundation #CTO2025 by rising 🌟 Enrico Poletti: identifying these pts is paramount to adopt preventive strategies (bailout MCS outcomes are very poor). UWashington Heart Institute

5- Finally, the best data that stuck with me and probably will affect my practice Outcomes presented by Taishi Hirai, led by Aaron Grantham. Bringing pt back after STAR at 5-7 weeks had numerically higher success rates compared with 12-14 weeks. My default was 8 weeks, and I